Literature DB >> 8661815

Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum.

B Stinner1, O Kisker, A Zielke, M Rothmund.   

Abstract

Carcinoid tumors occur most frequently in the gastrointestinal tract. Despite their ability to produce hormones, most of the midgut and hindgut carcinoids covered in this study are clinically silent, and the diagnosis is often not made before emergency surgery or evaluation for liver metastases. Because the rate of lymph node involvement and the prognosis of carcinoid tumors depend on their site and size, surgery refers to these two factors too. Lymph node metastases are most commonly found with small bowel carcinoids (20-45%), providing the rationale for an extended resection including the adjacent lymph node drainage area. Carcinoid tumors of the appendix < 1 cm in diameter rarely metastasize, simply requiring appendectomy for treatment. Lesions > 2 cm should be treated by right hemicolectomy because of their approximately 30% risk of lymph node metastases. Resection should always be done for carcinoid tumors of the colon resection as for adenocarcinomas. Rectal carcinoids < 2 cm rarely metastasize, directing the conclusion that for these smaller lesions local excision is sufficient; for lesions >2 cm a standard cancer resection should be performed provided distant metastases are absent. In general, the younger the patient or the larger the primary tumor, the more aggressive the treatment should be.

Entities:  

Mesh:

Year:  1996        PMID: 8661815     DOI: 10.1007/s002689900028

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  30 in total

1.  Partial abdominal evisceration and intestinal autotransplantation to resect a mesenteric carcinoid tumor.

Authors:  William H Kitchens; Nahel Elias; Lawrence S Blaszkowsky; A Benedict Cosimi; Martin Hertl
Journal:  World J Surg Oncol       Date:  2011-01-31       Impact factor: 2.754

Review 2.  [Classification of gastro-entero-pancreatic neuroendocrine tumors].

Authors:  A Perren; A Schmitt; P Komminoth; M Pavel
Journal:  Radiologe       Date:  2009-03       Impact factor: 0.635

3.  Gastrointestinal carcinoids: characterization by site of origin and hormone production.

Authors:  M W Onaitis; P M Kirshbom; T Z Hayward; F J Quayle; J M Feldman; H F Seigler; D S Tyler
Journal:  Ann Surg       Date:  2000-10       Impact factor: 12.969

4.  Isolated peritoneal carcinomatosis from gastrointestinal tract carcinoid tumor: two case reports and a review of the literature.

Authors:  Stacie Kahan; Nikhil Teppara; Robert Babkowski; Xiang Da Eric Dong
Journal:  Gastrointest Cancer Res       Date:  2013-01

5.  Carcinoid tumors of the appendix - last decade experience.

Authors:  Kleanthis Anastasiadis; Chrysostomos Kepertis; Vasilios Lampropoulos; Paschalis Tsioulas; Ioannis Spyridakis
Journal:  J Clin Diagn Res       Date:  2014-11-20

Review 6.  Perspective on the practical indications of endoscopic submucosal dissection of gastrointestinal neoplasms.

Authors:  Mitsuhiro Fujishiro
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

7.  Peritoneal carcinomatosis secondary to carcinoid tumour.

Authors:  J Ruiz-Tovar; N Alonso Hernández; V Morales Castiñeiras; E Lobo Martínez; A Sanjuanbenito Dehesa; E Martínez Molina
Journal:  Clin Transl Oncol       Date:  2007-12       Impact factor: 3.405

Review 8.  Current management of gastrointestinal carcinoid tumors.

Authors:  Kenneth J Woodside; Courtney M Townsend; B Mark Evers
Journal:  J Gastrointest Surg       Date:  2004 Sep-Oct       Impact factor: 3.452

Review 9.  Carcinoid tumors.

Authors:  Scott N Pinchot; Kyle Holen; Rebecca S Sippel; Herbert Chen
Journal:  Oncologist       Date:  2008-12-17

10.  [A rare case of a neuroendocrine carcinoma of the esophagus. Intermediate between a well-differentiated neuroendocrine carcinoma and a low-differentiated neuroendocrine carcinoma].

Authors:  T Gumprich; G Johnen; T Hummel; M Jaworska; I Schmitz; K-M Müller
Journal:  Pathologe       Date:  2004-05       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.